Publications by authors named "Paul Shami"

Claim this Profile
T
Tattooing and risk of melanoma: a population-based case-control study in Utah.
Rachel D McCarty, Britton Trabert, Lindsay J Collin, Morgan M Millar, David Kriebel, Paul J Shami

J Natl Cancer Inst· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma.
Shannuo Li, Jiahui Li, Hasan Al Faruque, Paul Shami, Birgit Knoechel

Adv Healthc Mater· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Martha L Arellano, Michael J Thirman, John F DiPersio, Maël Heiblig, Eytan M Stein, Paul J Shami

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base.
Nathan M Krah, Rasmus Hoeg, Paul J Shami, Shannon E Elf, Lauren E Lee

Leuk Res Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Natalie Wuliji, Salene M W Jones, Ted Gooley, Aaron T Gerds, Bruno C Medeiros, Paul J Shami

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin Inhibition With Revumenib for -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, John DiPersio, Martha Arellano, Paul J Shami

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bijal Shah, Ryan J Mattison, Ramzi Abboud, Peter Abdelmessieh, Ibrahim Aldoss, Paul Shami

J Natl Compr Canc Netw· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tattoos and Risk of Hematologic Cancer: A Population-Based Case-Control Study in Utah.
Rachel D McCarty, Britton Trabert, David Kriebel, Morgan M Millar, Brenda M Birmann, Paul J Shami

Cancer Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and/or CD38 receptors.
Jiahui Li, M Tommy Gambles, Brandt Jones, Justin A Williams, Nicola J Camp, Paul J Shami

Drug Deliv Transl Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy.
M Tommy Gambles, Shannuo Li, Isaac Kendell, Jiahui Li, Douglas Sborov, Paul Shami

ACS Nano· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations of demographic, health, and risk-taking behaviors with tattooing in a population-based cross-sectional study of ~18,000 US adults.
Rachel D McCarty, Britton Trabert, Morgan M Millar, David Kriebel, Laurie Grieshober, Paul J Shami

Res Sq· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors.
M Tommy Gambles, Douglas Sborov, Paul Shami, Jiyuan Yang, Jindřich Kopeček

Macromol Biosci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of JS-K, a First-in-Class Arylated Diazeniumdiolate, for the Treatment of Cancer.
Paul J Shami

Crit Rev Oncog· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
Daniel A Pollyea, Jessica K Altman, Rita Assi, Dale Bixby, Amir T Fathi, Paul J Shami

J Natl Compr Canc Netw· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Paul Shami

Blood· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres, Paul J Shami

Blood· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo.
M Tommy Gambles, Jiahui Li, D Christopher Radford, Douglas Sborov, Paul Shami

J Control Release· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-mediated depletion of programmed death 1-positive (PD-1) cells.
Yujia Zhai, Shuyun Dong, Haojia Li, Yue Zhang, Paul Shami

J Control Release· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
Peter L Greenberg, Richard M Stone, Aref Al-Kali, John M Bennett, Uma Borate, Paul J Shami

J Natl Compr Canc Netw· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA.
Justin Watts, Tara L Lin, Alice Mims, Prapti Patel, Cynthia Lee, Paul Shami

Front Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436.
Fatih M Uckun, Justin Watts, Alice S Mims, Prapti Patel, Eunice Wang, Paul J Shami

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Mohamed L Sorror, Barry E Storer, Amir T Fathi, Andrew Brunner, Aaron T Gerds, Paul J Shami

Blood· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Fatih M Uckun, Tara L Lin, Alice S Mims, Prapti Patel, Cynthia Lee, Paul J Shami

Cancers (Basel)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.
Kristen C Kelley, Kenneth F Grossman, Mary Brittain-Blankenship, Kelli M Thorne, Wallace L Akerley, Paul J Shami

BMC Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Daniel A Pollyea, Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K Altman, Paul J Shami

J Natl Compr Canc Netw· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis